#1
#1 out of 1
business7h ago
Adial Pharmaceuticals enters exclusive AD04 Europe framework with Molteni; potential $60M in royalties & milestones
- Adial signs an exclusive European framework with Molteni to commercialize AD04 in Europe.
- The framework grants Molteni exclusivity to evaluate feasibility and plan a European launch.
- Deal terms include upfront payment, development milestones, and tiered royalties.
- Total potential royalties and milestones could reach nearly $60 million over time.
- A special meeting on Feb 26 lacked a quorum, delaying approvals.
Vote 0